The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.本發明大體上係關於免疫學及分子生物學領域。更特定言之,本發明提供包含 (A)針對LY75之抗體或其抗原結合部分及(B)第二抗癌實體之醫藥組合;編碼抗體組合之核酸;製備抗體組合之方法;以及治療諸如由LY75表現或活性介導之癌症的疾病之方法。